JAZZ PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 110.7 USD | -0.46% |
|
+0.35% | -10.00% |
Presenter SpeechJacob Hughes (Analysts)Hi, everyone. We're going to go on to the next session....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
Pharmaceuticals
Calendar
2024-05-15
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
110.7
USD
Average target price
182
USD
Spread / Average Target
+64.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 7.01B | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Transcript : Jazz Pharmaceuticals plc Presents at 2022 Wells Fargo Healthcare Conference, Sep-08-2022 11